GenoMed -- ST. LOUIS—February 12, 2009—GenoMed® (OTC Pink Sheets GMED.PK) announced today that AstraZeneca’s study showing that high dose Atacand was better than low dose drug for patients with kidney failure fully supports results its CEO observed 15 years earlier.
